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Abstract
Cutaneous melanoma originates from pigment producing melanocytes or their precursors and is considered the deadliest form
of skin cancer. For the last 40 years, few treatment options were available for patients with late-stage melanoma. However,
remarkable advances in the therapy ﬁeld were made recently, leading to the approval of two new drugs, the mutant BRAF
inhibitor vemurafenib and the immunostimulant ipilimumab. Although these drugs prolong patients’ lives, neither drug cures
the disease completely, emphasizing the need for improvements of current therapies. Our knowledge about the complex
genetic and biological mechanisms leading to melanoma development has increased, but there are still gaps in our
understanding of the early events of melanocyte transformation and disease progression. In this review, we present a summary
of the main contributing factors leading to melanocyte transformation and discuss recent novel ﬁndings and technologies that
will help answer some of the key biological melanoma questions and lay the groundwork for novel therapies.
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Traditional targets and therapies
Melanoma is the most aggressive form of skin cancer,
causing 50,000 deaths annually worldwide, and its
incidencecontinuestoincrease.Ifthetumorisdetected
early, before it has invaded into the dermis, surgical
excision provides a cure in about 99% of patients.
However, the 5-year survival rate falls to 15% and to
a median survival of 1 year for those with advanced,
disseminated disease (1).
Until recently, there were few approved and
successful treatment options for advanced-stage
melanoma. Common treatment strategies included
conventional chemotherapy with dacarbazine
(DTIC) and the cytokines interleukin-2 (IL-2) and
interferon-a2b (IFN-a2b). While only 5%–10% of the
patients respond to DTIC treatment, IL-2 treatment
with the use of IFN-a2b as adjuvant immunotherapy
achieves a response in 10%–20% of patients (1).
Unfortunately, these responses are generally short-
lived and associated with high toxicity. Encour-
agingly, in recent years the identiﬁcation of the
main genetic aberrations and signaling pathways
involved in melanocyte transformation and disease
progression has resulted in the development of novel,
more effective therapeutic approaches.
The ﬁrst clues about the molecular basis of
melanoma came from studies of families prone to
the disease and the identiﬁcation of two autosomal-
dominant high-susceptibility loci: cyclin-dependent
kinase inhibitor 2A (CDKN2A) and cyclin-dependent
kinase 4 (CDK4). The CDKN2A locus encodes two
tumor suppressor proteins, p16
INK4a and p14
ARF.
While p16
INK4a is an inhibitor of the cyclin-dependent
kinases CDK4 and CDK6 and prevents S-phase entry
during cell cycle, p14
ARF acts as a positive regulator of
p53. Deletions of the CDKN2A locus have been found
in up to 50% of melanomas, but inactivation of
this locus can also occur through mutations and pro-
moter hypermethylation (2-4). Although undoubtedly
important for melanoma development, in terms of
therapy, direct targeting and restoring of the function
of tumor suppressor proteins have been inherently
difﬁcult.
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with the realization that the mitogen activated protein
kinase (MAPK) pathway is a crucial regulator of
melanoma development. In fact, activation of this
pathway regulates both proliferation and survival of
melanoma cells. The underlying mechanism of
MAPK deregulation is attributed to activating muta-
tions in NRAS and BRAF genes, resulting in a con-
stitutive activation of the pathway. In addition,
autocrine growth factors, adhesion molecule signal-
ing, and morphogen signalingall contribute to MAPK
pathway activation. While NRAS mutations are
observed in 15%–25% of melanomas, BRAF is
mutated in as many as 50% of the cases (5). In
addition, more than 95% of the mutations in BRAF
affect a valine residue at the 600 amino acid position
(BRAF
V600E), while the NRAS mutation is most
often a glutamine-to-arginine substitution at position
61 (NRAS
Q61R).
This increased knowledge about the molecular
changes in melanoma led to the application of sor-
afenib, the ﬁrst agent targeting the MAPK pathway.
Disappointingly, in phase II trials, sorafenib demon-
strated poor ability to inhibit MAPK pathway activa-
tion and little to no clinical efﬁcacy as a single agent.
The real advance came with the development of more
potent and selective BRAF
V600E inhibitors includ-
ing vemurafenib (PLX4032). Clinical results from
phase I, II, and III trials showed that vemurafenib
treatment caused complete or partial tumor regres-
sion in 80% of patients carrying BRAF
V600E tumors as
well as an increased progression-free survival rate
(6,7). Given this success, several other pharmacologi-
cal inhibitors targeting proteins of the MAPK path-
way, including MEK and ERK, are being developed
(8). Unfortunately, after an initial period of response
to vemurafenib, most patients relapse and develop
resistance to the drug (7). Resistance can be acquired
through several mechanisms including activation of
the serine/threonine kinase COT and RAF isoform
switching (9). Furthermore, we and others have
shown that the elevation of insulin-like growth factor
receptor (IGFR) or platelet-derived growth factor
receptor (PDGFR) confer resistance to BRAF
V600E
inhibitors through activation of the PI3K/Akt signal-
ing pathway (10-12), collectively suggesting that tar-
geting of the PI3K/Akt signaling pathway along
with the MAPK pathway might provide a new and
more effective therapeutic approach for melanoma
treatment.
Melanoma represents a heterogeneous group of
neoplasms with variable genotypic and phenotypic
traits based on anatomic location, degree of sun
exposure, and individual susceptibility. For instance,
several genetic studies indicate that acral and mucosal
melanomas develop through different etiological
pathways than cutaneous melanomas. In these sub-
types, the MAPK pathway is not activated through the
same mutation as in the cutaneous counterparts.
While BRAF mutations are signiﬁcantly less frequent
in these melanoma subtypes, activating mutations in
the KIT gene are often seen. KIT encodes a receptor
tyrosine kinase (c-Kit) that plays an important role in
the development, proliferation, and survival of mela-
nocytes (13). The therapeutic potential of targeting
c-KIT in this subgroup of melanomas was validated
by two clinical studies where patients with activating
mutations in c-KIT showed signiﬁcant responses to
the c-KIT inhibitor imatinib (14,15); however, overall
clinical responses to this inhibitor are less pronounced
than to BRAF inhibitors.
Numerous other molecular alterations contribute
to the complexity of melanoma biology, including
mutations of receptor tyrosine kinases ERBB4 and
EPH, activation of vascular endothelial growth factor
receptors (VEGFR), deregulation of p53, MITF
expression, and the developmental signaling pathways
Notch and Wnt (16-19). However, attempts to target
these pathways therapeutically have not been success-
ful so far.
Improved understanding of tumor immunobiology
has also provided novel treatment approaches for mel-
anoma. Ipilimumab is a monoclonal antibody that
augments T-cell activation and proliferation by block-
ing the cytotoxic T-lymphocyte antigen-4, a critical
negative regulator of the antitumor T-cell response. In
advanced-stage melanoma patients, treatment with
ipilimumab resulted in a 20% increased survival up
to 4 years after treatment (20). Nevertheless, only a
fraction of patients receive durable beneﬁts from ipi-
limumab therapy.
Thus, even though ipilimumab and vemurafenib
have created enthusiasm in the melanoma therapeutic
ﬁeld, it is evident that further improvements are
necessary. Likely, the key to further success in therapy
lies in combination therapies, in which two or more
drugs are combined. The lack of good therapeutic
targets outside of the MAPK pathway also underlines
the need for further analysis of currently known
drivers of melanocyte transformation and melanoma
progression as well as identiﬁcation of new ones.
The path to melanocyte transformation
Melanocytes develop during embryogenesis from
melanoblastic precursors that migrate from the neural
crest to populate the epidermis, hair follicles, cochlea,
and the uveal tract of the eye (21). Once situated
in the epidermis, melanocytes remain under tight
control by keratinocytes and proliferate only after
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atinocytes (22). Development and progression of
melanoma depends on a set of genetic alterations
that allow melanocytes to escape regulation by kera-
tinocytes, migrate, invade, and survive in a ‘hostile’
environment. These alterations are termed ‘drivers’ of
the disease. In addition to these alterations, the cells
also acquire many secondary or ‘passenger’ altera-
tions as a result of general genome instability, which is
particularly seen in melanoma cells. The ability to
distinguish the essential driver from passenger muta-
tions is critical to the development of effective
therapies.
Acquisition of the BRAF
V600E mutation is consid-
ered an early event in the initiation of melanocytic
neoplasia but in itself is not sufﬁcient for full transfor-
mation (Figure 1). For example, overexpression of
BRAF
V600E in melanocytes of transgenic zebraﬁsh
and mice induces nevus-like cell growth but does
not lead to melanoma development (23,24). In normal
human melanocytes (NHM), ectopic introduction of
BRAF
V600E in vitro leads to cellular senescence, an
irreversible form of cell cycle arrest (25). Senescence is
often characterized by phenotypic features, such
as increased senescence-associated b-galactosidase
(SA-b Gal) activity and elevated levels of negative
regulators of the cell cycle, such as p16
INK4a, p53,
and p21
CIP/WAF (25,26). Interestingly, both p16
INK4a
and p53 were reported to be dispensable for
BRAF
V600E-induced senescence in NHM, and the
exact mechanisms of this oncogene-induced senes-
cence (OIS) are still not fully understood (27,28).
However, it is assumed that OIS represents a major
barrier to oncogenic transformation which makes OIS
mechanisms important for further studies. Benign
nevi, which are considered non-proliferative melano-
cyte lesions, represent the best in vivo evidence of OIS.
BRAF
V600E mutations are found in 60% of benign nevi
and are thought to result in the initial increase in
proliferation ofmelanocytic cells followed by induction
of cell cycle arrest and senescence (29).
In addition to BRAF
V600E, overexpression of consti-
tutively active mutants of RAS, most commonly
HRAS
G12V and NRAS
Q61R,a l s ol e a d st oO I Si n
NHM. However, there are differences between mecha-
nisms of OIS induction in each case. For example,
HRAS
G12V-speciﬁc senescence can be mediated by
the endoplasmatic reticulum (ER)-associated unfolded
protein response (UPR) (27). Moreover, p16
INK4a,
p14
ARF, and p53 do not appear to play a prominent
co-operating role in the HRAS
G12V-induced senes-
cence. In the case of NRAS
Q61R, contribution of both
p53 and pRb is evident due to the fact that deple-
tion of either factor makes NHM refractory to senes-
cence induction (30). Collectively, these observations
underline mutation-speciﬁc differences in senescence
Benign nevus
OIS
Normal
melanocyte
BRAFV600E, NRASQ61R,KIT
initial proliferation
MAPK pathway PI3K/Akt pathway
PTEN loss
AKT3 amplification
Loss of p53, pRB, p16INKa
c-MYC activation
Dysplastic nevus Primary
melanoma
Metastatic
melanoma
Figure 1. Genetic alterations leading to bypass of oncogene-induced senescence (OIS) and transformation of melanocytes.
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inmelanomacellsandhastobetakenintoconsideration
when evaluating therapeutic approaches. In melanoma
cells RAS mutations are not equivalent to BRAF muta-
tions since they activate the MAPK pathway in different
ways. While BRAF mutationsresult in direct phosphor-
ylationandactivationofMEK,RASmutationsinducea
switch in signaling from BRAF to CRAF, allowing
CRAF to signal to MEK (31,32).
Since approximately 30% of melanomas arise from
nevi, these cells must have acquired additional altera-
tionsduringthetransformationprocessallowingthemto
overcome OIS. Recently it has been shown that the
ectopic expression of the oncogenic transcription factor
c-MYC can signiﬁcantly suppress OIS in NHM (28).
A similar effect is obtained by depletion of the B56a
subunit of the PP2A tumor suppressor complex, which
also leads to the up-regulation of endogenous c-MYC
(33).Hömig-Hölzeletal.demonstratedthatsuppression
ofthetranscriptionfactorandputativetumorsuppressor
gene TGFb-stimulated clone 22 (TSC22D1) allows
NHM to bypass BRAF
V600E-induced senescence (34).
Another protein recently reported to modulate OIS in
NHM is pirin, a highly conserved nuclear protein
belongingtothecupinsuperfamily14.Down-regulation
and overexpression experiments showed that pirin is
involved in the negative control of OIS and that its
expression is necessary to overcome the senescence
barrier (35). In addition, pirin controls melanoma cell
migration through the transcriptional regulation of snail
homolog 2 (SNAI2) (36).
Itisinterestingtospeculatewhetheracquisitionofthe
alterations allowing melanocytes to bypass OIS is suf-
ﬁcientforthedevelopmentofthemalignantphenotype.
Inanimalmodels,BRAF
V600Einducesmelanomawhen
combined with p16
INK4a/p14
ARF or p53 deﬁciency,
as well as when combined with the activation of
b-catenin that leads to silencing of p16
INK4a
(24,37-40). However, Dhomen et al. recently reported
that BRAF
V600E c a ni n d u c em e l a n o m ai nm i c ew i t h o u t
p16
INK4a inactivation.Still,theselesionsappearedafter
a long latency period, and it is possible that additional
unidentiﬁed genetic alterations have occurred during
this time (23).
Previously it has been shown that NHM immorta-
lized with the oncogenic simian virus 40 (SV40) large-
T, human telomerase reverse transcriptase, and
transduced with either HRAS
G12V or c-Met, gain
the ability to form tumors in vivo (41). In addition,
combined expression of MITF and BRAF
V600E also
led to transformation of NHM (42). In our in vitro
models, transformation of NHM without immorta-
lization by the SV40 can be achieved by combining
BRAF
V600E and inactivating both the p53 and Rb
pathways (43).
Increasing evidence supports the hypothesis that
activation of the PI3K/Akt pathway, which acts
upstream of both b-catenin and c-MYC, may also be
involved in melanocyte senescence suppression and
transformation (28,44). Chudnovsky et al. showed
that invasive human melanocytic neoplasia can be
induced by activation of PI3K when combined with
Rb and p53 inhibition as well as hTERT expression
(45). Interestingly, in the same study, BRAF
V600E did
not show the same oncogenic potential as PI3K, sug-
gesting that the effect of different genes on transforma-
tion depends on speciﬁc combinations and the timing
of mutational events as well as the experimental model
used. In contrast, expression of BRAF
V600E combined
with PTEN gene silencing induced melanomas with
100% penetrance, short latency, and metastatic disease
in a mouse model (44). In NHM, however, PTEN
deﬁciency combined with BRAF
V600E activation
induced a melanoma in situ-like phenotype without
dermal invasion in organotypic human skin culture.
Only after further addition of cell autonomous TGFb
did these lesions develop an invasive phenotype (46).
In addition to the MAPK and PI3K/Akt pathways,
other signaling networks are likely important for
OIS escape and melanocyte transformation. The
Notch signaling pathway, for example, plays a critical
role in the proper development of melanocytes from
neural crest precursors (reviewed in (47)). Upon
ligand activation, Notch receptors are proteolytically
cleaved, resulting in the liberation of the intracellular
domain (NIC) that translocates into the nucleus and
initiates transcription of target genes. Transduction of
primary melanocytes with this intracellular domain
leads to activation of the Notch signaling pathway
and induces a transformed phenotype in vitro (48).
However, NIC-transfected cells do not form tumors
in NOD-SCID mice, suggesting that Notch over-
expression in itself is not sufﬁcient for neoplastic
transformation.
Future perspectives; new knowledge through
new models
The identiﬁcation of novel drivers of OIS escape and
melanocyte transformation and the further characte-
rization of melanoma based on genetic subgroups are
critical for improving current therapies. In the last
few years, complex melanoma genetics have been
addressed by extensive genome-wide association
studies (GWAS). By comparing frequencies of
genetic polymorphisms, between melanoma patients
and healthy individuals, these studies aim to identify
novel melanoma susceptibility genes. Most of the
studies have analyzed single nucleotide polymorph-
isms (SNPs).The main advantage of this approach is
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collection. In melanoma, GWAS validated the impor-
tance of the well-known, high-penetrance alleles
CDKN2A and CDK4, while identifying several novel
low-risk alleles associated with increased melanoma
risk, including ATM, MX2, and CASP8 (49,50).
Furthermore, SNPs in the TERT and TRF1 genes,
that play important roles in the regulation of telome-
rase activity and telomere length, are signiﬁcantly
associated with an increased melanoma risk (51).
Interestingly, GWAS also found a novel TERT locus
(TERT CLPTM1) that is positively associated with
shorter telomere length and is inversely associated
with the melanoma risk. Previously, it has been shown
that there is a positive association between the number
and size of nevi and telomere length (52,53). Few
studies have addressed the role of telomerase in
evasion of OIS and transformation of melanocytes,
although recently Soo et al. reported that deregulation
of telomerase function occurs late in the disease
progression and not in early stages (54). Another
susceptibility locus was identiﬁed at 1q21.3 that spans
a region with ten genes, of which several are good
candidate genes for melanoma susceptibility, includ-
ing ARNT (Hif1b) and SETDB1 (49,55). In fact, it
was shown that SETDB1, which methylates histone
H3 on lysine 9 (H3K9), signiﬁcantly accelerates mel-
anoma formation in zebraﬁsh (56).
Additional advances in melanoma genetics have
also been made with improved next generation
sequencing technology. This allowed the comparison
of the complete DNA sequence of cancer cells to their
normal counterparts. Pleasance et al. catalogued the
complete spectrum of somatic mutations and rear-
rangements in the metastatic cell line COLO-829
using a lymphoblastoid cell line from the same patient
as a reference (57). This resulted in the identiﬁcation
of an astonishing total of 33,345 base substitutions of
which 292 were somatic mutations (187 non-
synonymous and 105 synonymous) in protein coding
sequences. Since the ratio between non-synonymous
and synonymous mutations did not signiﬁcantly
exceed random expectation, the majority of these
mutations were catalogued as ‘passengers’. Interest-
ingly, 70% of these mutations could be traced back to
DNA damage induced by ultraviolet radiation,
emphasizing its dominating role in melano magenesis.
Previously identiﬁed driver mutations in CDKN2A,
BRAF, and PTEN genes were conﬁrmed in this study,
while the oncogenes GLI1, ETV5, and tumor sup-
pressor genes DCC and TP63 were suggested as novel
potential drivers. In addition, mutations were seen in
the matrix metalloproteinase MMP28 gene. Other
novel but currently poorly characterized potential
‘driver’ genes included the transcription factor
encoding SPDEF, the serine/threonine kinase 19
encoding STK19 and XIRP2, which encodes xin
actin-binding repeat containing 2.
Collectively, GWAS and the next generation
sequencing studies have identiﬁed several novel
genes that might play a role in melanoma develop-
mentandprogression.However,extensivevalidation
of these genes will be necessary to elucidate the
mechanisms by which they contribute to melanocyte
transformation. In order to perform such validations
we must use and develop biologically adequate
experimentalmodels.Mostofourcurrentknowledge
isbasedoninvitrostudies,experimentalgrafting,and
transgenic animal melanoma models. Difﬁculties in
accessing relevant biological materials and recapitu-
lating genetic complexity have hampered the direct
analysisofdiseaseprogressioninhumans.Thiscould
p o s s i b l yb eo v e r c o m ei nt h en e a rf u t u r eb yt h e
use of human induced pluripotent stem cells
(hIPSCs). These pluripotent cells acquire most of
the features of embryonic stem cells (ESCs) and can
be differentiated into any cell type, including mela-
nocytes (58).
Recently, Nissan et al. demonstrated that use of
t h ec y t o k i n eb o n em o r p h o g e n i cp r o t e i n4a l l o w s
generation of fully functional melanocytes from plu-
ripotent stem cell lines of either induced or of
embryonic origin (59). These melanocytes exhibit
all the characteristic features of their adult counter-
parts, including the enzymatic machinery required
for the production and functional delivery of mela-
nin to keratinocytes. Furthermore, these cells inte-
grate appropriately into an organotypic epidermis
reconstructed in vitro.B ya p p l y i n gs u c hh I P S C
technology, we will be able to obtain melanocytes
from patients with genotypes of particular interest
via a simple skin biopsy using easily accessible ﬁbro-
blasts; hIPSC-derived melanocytes will retain the
patients’ complex genetic background, making it
possible to study the impact of the genotype on
disease development under a variety of experimen-
tally controlled conditions, which would lead to a
substantially better understanding of melanoma
biology. Furthermore, using melanocytes in the
correct genetic background would allow for testing
targeted therapies within the context of proper host
cells and thus provide new opportunities for target
identiﬁcation and validation.
Acknowledgements
Parts of these studies were funded by NIH grants CA
25874, CA 114046, CA 076674, and CA 047159 and
the Norwegian Cancer Society.
Narrowing the knowledge gaps for melanoma 241Declaration of interest: The authors report no
conﬂicts of interest. The authors alone are responsible
for the content and writing of the paper.
References
1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous
melanoma. N Engl J Med. 2004;351:998–1012.
2. Monahan KB, Rozenberg GI, Krishnamurthy J, Johnson SM,
Liu W, Bradford MK, et al. Somatic p16(INK4a) loss accel-
erates melanomagenesis. Oncogene. 2010;29:5809–17.
3. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ,
Kutzner H, et al. Distinct sets of genetic alterations in mel-
anoma. N Engl J Med. 2005;353:2135–47.
4. Meyle KD, Guldberg P. Genetic risk factors for melanoma.
Hum Genet. 2009;126:499–510.
5. Flaherty KT, Fisher DE. New strategies in metastatic mela-
noma: oncogene-deﬁned taxonomy leads to therapeutic
advances. Clin Cancer Res. 2011;17:4922–8.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P,
Larkin J, et al. Improved survival with vemurafenib in melanoma
with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.
7. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA,
Sosman JA, et al. Inhibition of mutated, activated BRAF in
metastatic melanoma. N Engl J Med. 2010;363:809–19.
8. Inamdar GS, Madhunapantula SV, Robertson GP. Targeting
the MAPK pathway in melanoma: Why some approaches
succeed and other fail. Biochem Pharmacol. 2010;80:624–37.
9. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF Inhi-
bitors: unraveling mechanisms and future treatment options.
Cancer Res. 2011;71:7137–40.
10. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al.
Melanomas acquire resistance to B-RAF(V600E) inhibition
by RTK or N-RAS upregulation. Nature. 2010;468:973–7.
11. Poulikakos PI, Rosen N. Mutant BRAF melanomas—depen-
dence and resistance. Cancer Cell. 2011;19:11–15.
12. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-
Kalabis M, Cipolla AK, et al. Acquired resistance to BRAF
inhibitors mediated by a RAF kinase switch in melanoma can
be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer
Cell. 2010;18:683–95.
13. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activa-
tion of KIT in distinct subtypes of melanoma. J Clin Oncol.
2006;24:4340–6.
14. Hodi FS, Friedlander P, Corless CL, Heinrich MC,
Mac Rae S, Kruse A, et al. Major response to imatinib
mesylate in KIT-mutated melanoma. J Clin Oncol. 2008;
26:2046–51.
15. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete
response to imatinib of a metastatic mucosal melanoma with
a K642E KIT mutation. Pigment Cell Melanoma Res. 2008;21:
492–3.
16. Box NF, Terzian T. The role of p53 in pigmentation, tanning
and melanoma. Pigment Cell Melanoma Res. 2008;21:
525–33.
17. Easty DJ, Gray SG, O’Byrne KJ, O’Donnell D, Bennett DC.
Receptor tyrosine kinases and their activation in melanoma.
Pigment Cell Melanoma Res. 2011;24:446–61.
18. O’Connell MP, Weeraratna AT. Hear the Wnt Ror: how
melanoma cells adjust to changes in Wnt. Pigment Cell
Melanoma Res. 2009;22:724–39.
19. Strizzi L, Hardy KM, Kirsammer GT, Gerami P,
Hendrix MJ. Embryonic signaling in melanoma: potential
for diagnosis and therapy. Lab Invest. 2011;91:819–24.
20. Hodi FS, O’Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, et al. Improved survival with ipili-
mumab in patients with metastatic melanoma. N Engl J Med.
2010;363:711–23.
21. Ernfors P. Cellular origin and developmental mechanisms
during the formation of skin melanocytes. Exp Cell Res.
2010;316:1397–407.
22. Haass NK, Herlyn M. Normal human melanocyte homeo-
stasis as a paradigm for understanding melanoma. J Investig
Dermatol Symp Proc. 2005;10:153–63.
23. Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R,
Savage K, Delmas V, et al. Oncogenic Braf induces melano-
cyte senescence and melanoma in mice. Cancer Cell. 2009;15:
294–303.
24. Patton EE, Widlund HR, Kutok JL, Kopani KR,
Amatruda JF, Murphey RD, et al. BRAF mutations are
sufﬁcient to promote nevi formation and cooperate with
p53 in the genesis of melanoma. Curr Biol. 2005;15:249–54.
25. Bansal R, Nikiforov MA. Pathways of oncogene-induced
senescence in human melanocytic cells. Cell Cycle. 2010;9:
2782–8.
26. Cagnol S, Chambard JC. ERK and cell death: mechanisms of
ERK-induced cell death—apoptosis, autophagy and senes-
cence. FEBS J. 2010;277:2–21.
27. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M,
Johnson TM, Fullen DR, et al. Anti-oncogenic role of the
endoplasmic reticulum differentially activated by mutations in
the MAPK pathway. Nat Cell Biol. 2006;8:1053–63.
28. Zhuang D, Mannava S, Grachtchouk V, Tang WH, Patil S,
Wawrzyniak JA, et al. C-MYC overexpression is required for
continuous suppression of oncogene-induced senescence in
melanoma cells. Oncogene. 2008;27:6623–34.
29. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M,
Robbins CM, et al. High frequency of BRAF mutations in
nevi. Nat Genet. 2003;33:19–20.
30. Haferkamp S, Tran SL, Becker TM, Scurr LL, Kefford RF,
Rizos H. The relative contributions of the p53 and pRb
pathways in oncogene-induced melanocyte senescence. Aging
(Albany NY). 2009;1:542–56.
31. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D,
CurtinJA,etal.Inmelanoma,RASmutationsareaccompanied
by switching signaling from BRAF to CRAF and disrupted
cyclic AMP signaling. Cancer Res. 2006;66:9483–91.
32. Pavey S, Johansson P, Packer L, Taylor J, Stark M,
Pollock PM, et al. Microarray expression proﬁling in mela-
noma reveals a BRAF mutation signature. Oncogene. 2004;
23:4060–7.
33. MannavaS,OmilianAR,WawrzyniakJA,FinkEE,ZhuangD,
Miecznikowski JC, et al. PP2A-B56alpha controls oncogene-
induced senescence in normal and tumor human melanocytic
cells. Oncogene. 2011;Aug8 [Epub ahead of print].
34. Homig-Holzel C, van Doorn R, Vogel C, Germann M,
Cecchini MG, Verdegaal E, et al. Antagonistic TSC22D1
variants control BRAF(E600)-induced senescence. EMBO J.
2011;30:1753–65.
35. Licciulli S, Luise C, Scafetta G, Capra M, Giardina G,
Nuciforo P, et al. Pirin inhibits cellular senescence in mela-
nocytic cells. Am J Pathol. 2011;178:2397–406.
36. Miyazaki I, Simizu S, Okumura H, Takagi S, Osada H.
A small-molecule inhibitor shows that pirin regulates migra-
tion of melanoma cells. Nat Chem Biol. 2010;6:667–73.
37. Ha L, Ichikawa T, Anver M, Dickins R, Lowe S,
Sharpless NE, et al. ARF functions as a melanoma tumor
suppressor by inducing p53-independent senescence. Proc
Natl Acad Sci USA. 2007;104:10968–73.
242 A. Slipicevic & M. Herlyn38. Delmas V, Beermann F, Martinozzi S, Carreira S,
Ackermann J, Kumasaka M, et al. Beta-catenin induces
immortalization of melanocytes by suppressing p16INK4a
expression and cooperates with N-Ras in melanoma develop-
ment. Genes Dev. 2007;21:2923–35.
39. Ackermann J, Beermann F. The ﬁbroblast growth factor-2 is
not essential for melanoma formation in a transgenic mouse
model. Pigment Cell Res. 2005;18:315–19.
40. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-
Cardo C, et al. Cooperative effects of INK4a and ras in mela-
noma susceptibility in vivo. Genes Dev. 1997;11:2822–34.
41. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S,
Kuo WL, Gray JW, et al. The melanocyte differentiation
program predisposes to metastasis after neoplastic transfor-
mation. Nat Genet. 2005;37:1047–54.
42. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ,
Ramaswamy S, et al. Integrative genomic analyses identify
MITF as a lineage survival oncogene ampliﬁed in malignant
melanoma. Nature. 2005;436:117–22.
43. Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, et al. The
role of BRAF mutation and p53 inactivation during transfor-
mation of a subpopulation of primary human melanocytes.
Am J Pathol. 2009;174:2367–77.
44. Dankort D, Curley DP, Cartlidge RA, Nelson B,
Karnezis AN, Damsky WE Jr, et al. Braf(V600E) cooperates
with Pten loss to induce metastatic melanoma. Nat Genet.
2009;41:544–52.
45. Chudnovsky Y, Adams AE, Robbins PB, Lin Q, Khavari PA.
Use of human tissue to assess the oncogenic activity of
melanoma-associated mutations. Nat Genet. 2005;37:745–9.
46. Lo RS, Witte ON. Transforming growth factor-beta activation
promotes genetic context-dependent invasion of immortalized
melanocytes. Cancer Res. 2008;68:4248–57.
47. Schouwey K, Beermann F. The Notch pathway: hair graying
and pigment cell homeostasis. Histol Histopathol. 2008;23:
609–19.
48. Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K,
Beverly LJ, et al. Active Notch1 confers a transformed pheno-
type to primary human melanocytes. Cancer Res. 2009;69:
5312–20.
49. Amos CI, Wang LE, Lee JE, Gershenwald JE, Chen WV,
Fang S, et al. Genome-wide association study identiﬁes novel
loci predisposing to cutaneous melanoma. Hum Mol Genet.
2011;20:5012–23.
50. Barrett JH, Iles MM, Harland M, Taylor JC, Aitken JF,
Andresen PA, et al. Genome-wide association study identiﬁes
three new melanoma susceptibility loci. Nat Genet. 2011;43:
1108–13.
51. Nan H, Qureshi AA, Prescott J, De Vivo I, Han J. Genetic
variants in telomere-maintaining genes and skin cancer risk.
Hum Genet. 2011;129:247–53.
52. Bataille V, Kato BS, Falchi M, Gardner J, Kimura M,
Lens M, et al. Nevus size and number are associated with
telomerelengthand representpotentialmarkersof a decreased
senescence in vivo. Cancer Epidemiol Biomarkers Prev. 2007;
16:1499–502.
53. Han J, Qureshi AA, Prescott J, Guo Q, Ye L, Hunter DJ, et al.
A prospective study of telomere length and the risk of skin
cancer. J Invest Dermatol. 2009;129:415–21.
54. Soo JK, Mackenzie Ross AD, Kallenberg DM, Milagre C,
Heung Chong W, Chow J, et al. Malignancy without immor-
tality? Cellular immortalization as a possible late event in
melanoma progression. Pigment Cell Melanoma Res. 2011;
24:490–503.
55. Macgregor S, Montgomery GW, Liu JZ, Zhao ZZ,
Henders AK, Stark M, et al. Genome-wide association study
identiﬁes a new melanoma susceptibility locus at 1q21.3. Nat
Genet. 2011;43:1114–18.
56. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S,
Orlando DA, Battisti V, et al. The histone methyltransferase
SETDB1 is recurrently ampliﬁed in melanoma and acceler-
ates its onset. Nature. 2011;471:513–17.
57. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ,
Humphray SJ, Greenman CD, et al. A comprehensive cata-
logue of somatic mutations from a human cancer genome.
Nature. 2010;463:191–6.
58. Yang R, Jiang M, Kumar SM, Xu T, Wang F, Xiang L, et al.
Generation of melanocytes from induced pluripotent stem
cells. J Invest Dermatol. 2011;131:2458–66.
59. Nissan X, Larribere L, Saidani M, Hurbain I, Delevoye C,
Feteira J, et al. Functional melanocytes derived from
human pluripotent stem cells engraft into pluris-
tratiﬁed epidermis. Proc Natl Acad Sci USA. 2011;108:
14861–6.
Narrowing the knowledge gaps for melanoma 243